Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 2/20 | 0.51 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.34 |
| ▸ | NMT1 | P30419 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10207383 | 0.90 | NR1I2 (0.51) | NR1I2CYP2E1OPRM1 | |
| SCHEMBL173160 | 0.89 | NR1I2 (0.42) | NR1I2CYP2E1 | |
| SCHEMBL12949395 | 0.88 | NR1I2 (0.49) | NR1I2CYP2E1OPRM1 | |
| SCHEMBL9965151 | 0.88 | NR1I2 (0.47) | NR1I2CYP2E1 | |
| SCHEMBL173093 | 0.88 | NR1I2 (0.47) | NR1I2CYP2E1 | |
| SCHEMBL12945459 | 0.87 | NR1I2 (0.47) | NR1I2CYP2E1 | |
| SCHEMBL12514089 | 0.87 | NR1I2 (0.43) | NR1I2CYP2E1NMT1MAPT | |
| SCHEMBL12514486 | 0.86 | NR1I2 (0.46) | NR1I2CYP2E1MAPT | |
| SCHEMBL12819798 | 0.86 | NR1I2 (0.46) | NR1I2CYP2E1 | |
| SCHEMBL12514339 | 0.86 | NR1I2 (0.48) | NR1I2CYP2E1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120301430-A1 | THIOPHENE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2012-11-29 | — | — | US | disclosed |
| US-8269014-B2 | Thiophene analogues for the treatment or prevention of flavivirus infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2012-09-18 | — | — | US | disclosed |
| US-8003685-B2 | Thiophene analogues for the treatment or prevention of flavivirus infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2011-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120301430-A1 | THIOPHENE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | TTR, ZC3HAV1, IRF3 | NR1I2 388/4885CYP2E1 98/4885OPRM1 3528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.